To study some blood tests which would help predict severity and outcome in children with cancers having the novel corona virus infection.
Not Applicable
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: D499- Neoplasm of unspecified behavior of unspecified site
- Registration Number
- CTRI/2020/05/025327
- Lead Sponsor
- O SPONSOR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All children with cancer who are undergoing treatment under Pediatric Haematology and Oncology will be included.
Exclusion Criteria
Patients who do not give consent to be included
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method For every child with febrile illness, the following outcomes will be measured: (1) clinical outcomes of infections (if any) including severity (pneumonia, multi-organ failure, death) and time to recover.Timepoint: Outcomes will be measured at baseline, week1, week2, week3 and at week4. Antibody response will be measured at week 4 and at 3 months.
- Secondary Outcome Measures
Name Time Method Other outcome pertaining to the malignancy which includes disease remission, progression, relapse and death will be noted if they occurred during the study frameTimepoint: during the time frame of study of 1 year